The role of IL-33 in Severity of Systemic Sclerosis
Mostafa, M., ELshourbagy, E., Elsayed, R. (2022). The role of IL-33 in Severity of Systemic Sclerosis. EKB Journal Management System, 31(2), 1-5. doi: 10.21608/ejmm.2022.228611
Mysa Mostafa; Eman wagih ELshourbagy; Rasha Abdel Hamid Elsayed. "The role of IL-33 in Severity of Systemic Sclerosis". EKB Journal Management System, 31, 2, 2022, 1-5. doi: 10.21608/ejmm.2022.228611
Mostafa, M., ELshourbagy, E., Elsayed, R. (2022). 'The role of IL-33 in Severity of Systemic Sclerosis', EKB Journal Management System, 31(2), pp. 1-5. doi: 10.21608/ejmm.2022.228611
Mostafa, M., ELshourbagy, E., Elsayed, R. The role of IL-33 in Severity of Systemic Sclerosis. EKB Journal Management System, 2022; 31(2): 1-5. doi: 10.21608/ejmm.2022.228611

The role of IL-33 in Severity of Systemic Sclerosis

Egyptian Journal of Medical Microbiology
Article 1, Volume 31, Issue 2, April 2022, Page 1-5  XML PDF (177.57 K)
Document Type: New and original researches in the field of Microbiology.
DOI: 10.21608/ejmm.2022.228611
View on SCiNiTO View on SCiNiTO
Authors
Mysa Mostafa email 1; Eman wagih ELshourbagy2; Rasha Abdel Hamid Elsayed3
1Microbiology and Immunology Department Faculty of Medicine Benha University
2rehumatology and rehabilitation benha faculty of medicine benha university
31Department of Medical Microbiology and Immunology, Faculty of Medicine, Benha University
Abstract
Background: Systemic sclerosis (SSc) is an autoimmune connective tissue disorder characterized by sclerotic changes which affect the skin and internal organs. Interleukin-33 (IL-33) is a newly reported cytokine of the IL-1 family.  Objective: The aim of this work was to determine serum levels of IL-33 in SSc patients and evaluate its association with clinical manifestations and disease subset. Methodology: The study included two groups. Group A included 40 adult patients diagnosed asSSc, these were subdivided into diffuse systemic sclerosis (dSSc) and limited systemic sclerosis (lSSc) groups. All patients were diagnosed according to the ACR criteria for SSc. Group B included 20 healthy adult persons (age and sex matched) as the control group. All patients were selected from the Rheumatology department Benha University Hospital. Serum IL-33 levels were examined by means of enzyme-linked immunosorbent assay. Result: mean serum level of IL-33 were highly significant in SS patients in comparison to control groups [p < 0.0001]. The levels of IL-33 were significantlyhigher in the dSSc subset compared with the lSSc subset. Also there was a statistically significant correlation between disease activity and serum levels of IL33.  Conclusion: IL-33 may have a significant role in the pathogenesis of SSc. IL-33 serum levels paralleled the severity of the disease subset. Understanding of IL-33 functions is important for the development of new therapeutic approaches including IL-33 inhibitors and IL-33 receptor blockers as a therapeutic target.
Keywords
Systemic Sclerosis; IL33; ELISA
Statistics
Article View: 197
PDF Download: 153